Role of autologous stem cell transplantation in chronic lymphocytic leukemia

Current Opinion in Hematology

Volumn 10, Issue 4, 2003, Pages 306-311

  Rizouli, Vassiliki ^a,b   Gribben, John G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTAMINATION; DISEASE COURSE; FLOW CYTOMETRY; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT OUTCOME;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 0038307418     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200307000-00009     Document Type: Review

References (62)

1. Keating MJ, O'Brien S, McLaughlin P, et al.: Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 1996, 38(suppl 2):S83-S91.
2. Hallek M, Schmitt B, Wilhelm M, et al.: Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 2001, 114:342-348.
3. Bosch F, Ferrer A, Lopez-Guillermo A, et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002, 119:976-984.
4. Byrd JC, Peterson BL, Morrison VA, et al.: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003, 101:6-14.
5. Schulz H, Klein SK, Rehwald U, et al.: Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002, 100:3115-3120.
6. Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554-3561.
7. Rai KR, Freter CE, Mercier RJ, et al.: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002, 20:3891-3897.
8. Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
9. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
10. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
11. Krober A, Seiler T, Benner A, et al.: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100:1410-1416.
12. Ritgen M, Lange A, Stilgenbauer S, et al.: Unmutated immunoglobulin variable heavy chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood Blood. 2003 Mar 1;101:2049-2053. These authors investigated the immunoglobulin V variable heavy chain (IgVH) mutational status by multiplex PCR and direct sequencing of 58 patients with CLL who underwent myeloablative radiochemotherapy with HCT. Twenty patients had a mutated IgVH status (less than 98% homology to germline VH sequences), and 38 had an unmutated VH status. An unmutated status was correlated with the presence of other predictors of poor prognosis, such as short lymphocyte doubling time and high lymphocyte count. These results imply that the IgVH mutational status remains an adverse prognostic parameter after autologous HCT. This study also demonstrated that this high-risk population could benefit from autologous HCT (only three deaths, median treatment-free interval of 49 months).
13. Hamblin TJ, Orchard JA, Gardiner A, et al.: Immunoglobulin V genes and CD38 expression in CLL. Blood 2000, 95:2455-2457.
14. Hallek M, Langenmayer I, Nerl C, et al.: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999, 93:1732-1737.
15. Molica S, Levato D, Cascavilla N, et al.: Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999, 62:117-122.
16. Philip T, Armitage JO, Spitzer G, et al.: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987, 316:1493-1498.
17. Fouillard L, Laporte JP, Labopin M, et al.: Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation-results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998, 16:2803-2816.
18. Gribben JG: Stem-cell transplantation for indolent lymphoma. Semin Hematol 1999, 36:18-25.
19. Dreger P, Michallet M, Schmitz N: Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective. Ann Oncol 2000, 11 (suppl 1):49-53.
20. Sala R, Mauro FR, Bellucci R, et al.: Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy. Eur J Haematol 1998, 61:14-20.
21. Michallet M, Thiebaut A, Dreger P, et al.: Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000, 108:595-601.
22. Schmitz N, Linch DC, Dreger P, et al.: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
23. Andre M, Henry-Amar M, Blaise D, et al.: Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998, 92:1933-1940.
24. Narayanasami U, Kanteti R, Morelli J, et al.: Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001, 98:2059-2064.
25. Scime R, Indovina A, Santoro A, et al.: PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Bone Marrow Transplant 1998, 22:1159-1165.
26. Dreger P, von Neuhoff N, Kuse R, et al.: Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer 1998, 77:2291-2297.
27. Pavletic ZS, Bierman PJ, Vose JM, et al.: High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 1998, 9:1023-1026.
28. Sutton L, Maloum K, Gonzalez H, et al.: Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia 1998, 12:1699-1707.
29. Gahn B, Schafer C, Neef J, et al.: Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia. Blood 1997, 89:4275-4281.
30. Gupta D, Bybee A, Cooke F, et al.: CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol 1999, 104:166-177.
31. Stewart AK, Vescio R, Schiller G, et al.: Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001, 19:3771-3779.
32. Barbui AM, Galli M, Dotti G, et al.: Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002, 116:202-210.
33. Holmberg LA, Boeckh M, Hooper H, et al.: Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999, 94:4029-4035.
34. Crippa F, Holmberg L, Carter RA, et al.: Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:281-289. This group investigates the incidence of non-cytomegalovirus viral, bacterial, and fungal infections in 32 patients who received CD34-selected autologous stem cell transplants, compared with 273 patients who received unselected autologous PBSCs. They report a significant increase in non-CMV viral infections, especially VZV and parainfluenza 3 virus infections. The incidence of bacterial infections was also increased in the CD34-selected transplant recipients. No significant difference was noted in the occurrence of fungal infections between the two groups. However, the infection-related mortality was not significantly different.
35. Altes A, Sierra J, Esteve J, et al.: CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Exp Hematol 2002, 30:824-830. In this study, a double purging procedure, a positive CD34 and negative CD19 selection was used in 26 patients with poor-prognosis lymphoproliferative disorders. Thirteen mobilized enough CD34 cells to proceed with the double purging protocol. Twelve became PCR-negative after purging. All but one engrafted without delay. Two had a molecular relapse at 7 and 19 months, respectively. Only one experienced a clinical relapse. Three patients had life-threatening infections. Another three died because of bronchiolitis obliterans, pneumococcal sepsis, and septic shock. Although this method, was feasible in 50% of the patients, who achieved a molecular remission and a low relapse rate, it was associated with a high morbidity and mortality.
36. Webb IJ, Friedberg W, Gribben JG, et al.: Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2002, 8:429-434. In this study, 10 patients with relapsed B-cell NHL received high-dose chemotherapy, followed by infusion of autologous stem cells depleted of B-cells by high-density microparticles coated with anti-CD19 and anti-CD20 monoclonal antibodies. After treatment, there were no detectable B cells in five of six patients who had B cells detectable by immunocytochemical analysis before treatment. Rapid engraftment was documented in all cases. The method was simple and effective. The relapse rate and the overall survival of the patients after transplant were not discussed.
37. Berkahn L, Simpson D, Raptis A, et al.: In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia. J Hematother Stem Cell Res 2002, 11:315-320. In this study, five patients with advanced-stage CLL undergoing autologous HCT received rituximab after cyclophosphamide and G-CSF/granulocyte-macrophage colony-stimulating factor mobilization as an in vivo purging step. Purging with tituximab 48 hours before stem cell collection resulted in a significant reduction (but not elimination) of the CLL cells in the leukapheresis. Interestingly, although CD5+/CD19+ cells were infused along with the stem cells, patients were able to obtain durable complete molecular remissions, implying that the PCR-positive cells in the leukapheresis may not have long-term clonogenic potential. The question of whether rituximab should be part of the maintenance regimen after transplant is one of the issues supported here that must be investigated in further studies.
38. Meloni G, Proia A, Mauro F, et al.: Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring. Haematologica 2000, 85:952-960.
39. Milpied N, Gaillard F, Moreau P, et al.: High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998, 22:645-650.
40. Stein RS, Greer JP, Goodman S, et al.: Is total body irradiation a necessary component of preparative therapy for autologous transplantation in non-Hodgkin's lymphoma. Leuk Lymphoma 2001, 41:97-103.
41. Gutierrez-Delgado F, Maloney DG, Press OW, et al.: Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant 2001, 28:455-461.
42. Dreger P, Montserrat E: Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002, 16:985-992. This is a comprehensive review of the role of the HCT treatment approach in CLL. The authors discuss the impact of the different HCT treatment modalities on the outcome and the prognosis of patients with CLL. They also define parameters that can be valuable in identifying those subgroups of patients who are likely to benefit by the application of either autologous or allogeneic HCT.
43. Rawstron AC, Kennedy B, Evans PA, et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
44. Provan D, Bartlett-Pandite L, Zwicky C, et al.: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88:2228-2235.
45. Magnac C, Sutton L, Cazin B, et al.: Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 1999, 41:13-18.
46. Marolleau JP, Brice P, Morel P, et al.: Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas. J Clin Oncol 1993, 11:590-591.
47. Stone RM: Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood 1994, 83:3437-3440.
48. Kumar L: Secondary leukaemia after autologous bone marrow transplantation. Lancet 1995, 345:810.
49. Gilliland DG, Gribben JG: Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:9-16.
50. Darrington DL, Vose JM, Anderson JR, et al.: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotheraphy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994, 12:2527-2534.
51. Laurenti L, Chiusolo P, Garzia MG, et al.: Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with tymphoproliferative malignancies. Haematologica 2002, 87:59-66. This study analyzed 66 patients undergoing autologous PBSC transplantation for HD, NHL, MM, or CLL who were in continuous complete remission after transplantation for at least 12 months and demonstrated no cytogenetic abnormalities or myelodysplastic features. There was no myelodysplastic syndrome/AML observed. The lack of exposure to risk factors that are associated with occurrence of myelodysplastic syndrome/AML was considered as a possible explanation for this finding.
52. Miller JS, Arthur DC, Litz CE, et al.: Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994, 83:3780-3786.
53. Govindarajan R, Jagannath S, Flick JT, et al.: Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996, 95:349-353.
54. Witherspoon RP, Deeg HJ, Storer B, et al.: Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001, 19:2134-2141.
55. Radich JP, Gooley T, Sanders JE, et al.: Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000, 6:272-279.
56. Friedberg JW, Neuberg D, Stone RM, et al.: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3128-3135.
57. McSweeney PA, Niederwieser D, Shizuru JA, et al.: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
58. Khouri IF, Keating M, Korbling M, et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824.
59. Dreger P, Glass B, Seyfarth B, et al.: Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous HCT. Bone Marrow Transplant 2000, 26:1361-1362.
60. Branson K, Chopra R, Kottaridis PD, et al.: Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20:4022-4031. This study investigates the efficacy of HLA-matched sibling nonmyeloablative allogeneic HCT with donor lymphocyte infusion in patients with lymphoid malignancy after failure of autologous HCT. It was performed on 38 patients who developed refractory, progressive, or relapsed disease after autologous HCT. The conditioning regimen consisted of campath-1H, fludarabine, and mephalan. Thirty-five patients were assessable; 15 of them received donor lymphocyte infusion after HCT. The transplant-related mortality was 7.9% at day 100 and 20% at 14 months. The overall survival at 14 months was 53%. The progression-free survival was 50%. This approach is presented here as a relatively safe option compared with conventional allogeneic transplantation for patients.
61. Cull GM, Haynes AP, Byrne JL, et al.: Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 2000, 108:754-760.
62. Carella AM, Cavaliere M, Lerma E, et al.: Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000, 18:3918-3924.